Search Within

Wassim Abida

Formats
  1. Meeting Abstract (75)
  2. Journal Article (72)
  3. Review (5)
  4. Editorial (4)
  5. Research Letter (2)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (160)
  2. Genitourinary Oncology Service (160)
  3. Solid Tumor Oncology Division (160)
  4. GSK Faculty (72)
  5. Human Oncology and Pathogenesis Program (68)
  6. Sloan Kettering Institute Postdocs (60)

More Groups

People
  1. Howard Scher (68)
  2. Michael Morris (39)
  3. David Solit (36)
  4. Nikolaus Schultz (33)
  5. Anuradha Gopalan (31)
  6. Dana Rathkopf (31)

More People

Years
  1. 2025 (10)
  2. 2024 (10)
  3. 2023 (14)
  4. 2022 (15)
  5. 2021 (19)
  6. 2020 (27)

More Years

Publications
  1. Journal of Clinical Oncology (40)
  2. Clinical Cancer Research (15)
  3. Annals of Oncology (13)
  4. Cancer Research (13)
  5. European Urology (8)
  6. JCO Precision Oncology (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (44)
  2. American Association for Cancer Research (31)
  3. Nature Publishing Group (17)
  4. Oxford University Press (13)
  5. Elsevier Science, Inc. (10)
  6. Nature Research (5)

More Publishers

Results (160)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of PARP inhibitor and platinum therapy on clonal hematopoiesis
    Meeting Abstract

    Baeten, J. T.; Chan, I. C. C.; Moukarzel, L.; Carter, A. C.; Patel, M.; Stopsack, K. H.; Pharoah, P.; Brenton, J.; Li, B. T.; Abida, W.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer
    Journal Article

    Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
    Journal of Immunotherapy and Precision Oncology (2023)

    Fulltext@MSK | Save
  • A multi-center natural history study of precision-based genomics in prostate cancer (PC)
    Meeting Abstract

    Beltran, H.; Mateo, J.; Abida, W.; McKay, R. R.; Montgomery, R.t B.; Aggarwal, Rahul Raj; Lee-Wisdom, K.; Figg, W. D.; Dahut, W. L.; Karzai, F.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: Final results from the phase 2 TRITON2 study
    Journal Article

    Abida, W.; Campbell, D.; Patnaik, A.; Bryce, A. H.; Shapiro, J.; Bambury, R. M.; Zhang, J.; Burke, J. M.; Castellano, D.; Font, A.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • PARP inhibitors for prostate cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) blues
    Editorial

    Beije, N.; Abida, W.; Antonarakis, E. S.; Castro, E.; de Wit, R.; Fizazi, K.; Gillessen, S.; Hussain, M.; Mateo, J.; Morris, M. J.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer
    Editorial

    Abida, W.; Attard, G.
    Lancet (2023)

    Fulltext@MSK | Save
  • Combining poly(ADP)-ribose polymerase inhibitors with abiraterone in castration-resistant prostate cancer: Is biomarker testing necessary?
    Editorial

    Antonarakis, E. S.; Abida, W.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical impact of a rapid genetic testing model for advanced prostate cancer patients
    Journal Article

    Breen, K. E.; Symecko, H.; Spielman, K.; Gebert, R.; Shah, I. H.; Pundock, S.; Batson, M.; Narayan, V. K.; Stadler, Z. K.; Autio, K. A.; more...
    Journal of Urology (2023)

    Fulltext@MSK | Save
  • Rucaparib or physician's choice in metastatic prostate cancer
    Journal Article

    Fizazi, K.; Piulats, J. M.; Reaume, M. N.; Ostler, P.; MeDermott, R.; Gingerich, J. R.; Pintus, E.; Sridhar, S. S.; Bambury, R. M.; Emmenegger, U.; more...
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save
  • Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy
    Meeting Abstract

    Bryce, A. H.; Piulats, J. M.; Reaume, M. N.; Ostler, P. J.; McDermott, R. S.; Gingerich, J. R.; Pintus, E.; Sridhar, S. S.; Abida, W.; Daugaard, G.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save